XPH vs. ARKG
XPH (SPDR S&P Pharmaceuticals ETF) and ARKG (ARK Genomic Revolution Multi-Sector ETF) are both Health & Biotech Equities funds. XPH is passively managed, while ARKG is actively managed. Over the past 10 years, XPH returned 3.44%/yr vs 7.22%/yr for ARKG. A 0.67 correlation means they provide meaningful diversification when combined. XPH charges 0.35%/yr vs 0.75%/yr for ARKG.
Performance
XPH vs. ARKG - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XPH achieves a 0.66% return, which is significantly lower than ARKG's 17.09% return. Over the past 10 years, XPH has underperformed ARKG with an annualized return of 3.44%, while ARKG has yielded a comparatively higher 7.22% annualized return.
XPH
- 1D
- 1.10%
- 1M
- -4.74%
- YTD
- 0.66%
- 6M
- 4.44%
- 1Y
- 37.98%
- 3Y*
- 13.07%
- 5Y*
- 3.50%
- 10Y*
- 3.44%
ARKG
- 1D
- -0.24%
- 1M
- 10.92%
- YTD
- 17.09%
- 6M
- 10.02%
- 1Y
- 53.35%
- 3Y*
- 0.67%
- 5Y*
- -15.72%
- 10Y*
- 7.22%
XPH vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
XPH SPDR S&P Pharmaceuticals ETF | 0.66% | 31.60% | 4.94% | 2.97% | -9.83% | -10.54% | 14.68% | 25.61% | -15.32% | 12.05% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 17.09% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 44.00% | -1.26% | 46.61% |
Correlation
The correlation between XPH and ARKG is 0.65, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.65 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.66 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.70 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.68 |
Correlation (All Time) Calculated using the full available price history since Nov 3, 2014 | 0.67 |
The correlation between XPH and ARKG has been stable across timeframes, ranging from 0.65 to 0.70 - a consistent structural relationship.
XPH vs. ARKG - Sectors Allocation Comparison
Sectors
XPH
ARKG
Healthcare
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
XPH
ARKG
Basic Materials
XPH
-
ARKG
-
Communication Services
XPH
-
ARKG
-
Consumer Cyclical
XPH
-
ARKG
-
Consumer Defensive
XPH
-
ARKG
-
Energy
XPH
-
ARKG
-
Financial Services
XPH
-
ARKG
Industrials
XPH
-
ARKG
-
Real Estate
XPH
-
ARKG
-
Technology
XPH
-
ARKG
-
Utilities
XPH
-
ARKG
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XPH vs. ARKG — Risk / Return Rank
XPH
ARKG
XPH vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XPH | ARKG | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.77 | 1.31 | +0.47 |
Sortino ratioReturn per unit of downside risk | 2.51 | 1.99 | +0.52 |
Omega ratioGain probability vs. loss probability | 1.30 | 1.22 | +0.07 |
Calmar ratioReturn relative to maximum drawdown | 3.19 | 1.95 | +1.24 |
Martin ratioReturn relative to average drawdown | 11.37 | 4.67 | +6.71 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| XPH | ARKG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.77 | 1.31 | +0.47 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.17 | -0.35 | +0.52 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.16 | 0.18 | -0.02 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.38 | 0.13 | +0.25 |
Drawdowns
XPH vs. ARKG - Drawdown Comparison
The maximum XPH drawdown since its inception was -48.03%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for XPH and ARKG.
Loading charts...
Drawdown Indicators
| XPH | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -48.03% | -83.59% | +35.56% |
Max Drawdown (1Y)Largest decline over 1 year | -11.97% | -27.51% | +15.54% |
Max Drawdown (3Y)Largest decline over 3 years | -23.57% | -51.96% | +28.39% |
Max Drawdown (5Y)Largest decline over 5 years | -31.63% | -80.18% | +48.55% |
Max Drawdown (10Y)Largest decline over 10 years | -35.97% | -83.59% | +47.62% |
Current DrawdownCurrent decline from peak | -7.22% | -69.65% | +62.43% |
Average DrawdownAverage peak-to-trough decline | -17.25% | -35.87% | +18.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.35% | 11.46% | -8.11% |
Volatility
XPH vs. ARKG - Volatility Comparison
The current volatility for SPDR S&P Pharmaceuticals ETF (XPH) is 7.03%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 11.90%. This indicates that XPH experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XPH | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.03% | 11.90% | -4.87% |
Volatility (6M)Calculated over the trailing 6-month period | 16.77% | 28.77% | -12.00% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.52% | 41.12% | -19.60% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.84% | 45.61% | -24.77% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.10% | 41.12% | -19.02% |
XPH vs. ARKG - Expense Ratio Comparison
XPH has a 0.35% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Dividends
XPH vs. ARKG - Dividend Comparison
XPH's dividend yield for the trailing twelve months is around 0.66%, while ARKG has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% | 0.00% | 0.00% |
XPH SPDR S&P Pharmaceuticals ETF | 0.66% | 0.83% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% |
Frequently Asked Questions
XPH and ARKG have a correlation of 0.65, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ARKG has higher volatility (11.90%) compared to XPH (7.03%). In terms of maximum drawdown, XPH dropped -48.03% vs ARKG's -83.59%.
On 10-year performance, ARKG leads with 7.22% vs 3.44% for XPH. On fees, XPH is cheaper at 0.35% per year. On volatility, XPH has been the lower-risk option at 7.03%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, ARKG has performed better with a 7.22% return vs 3.44%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
XPH is cheaper with a 0.35% expense ratio, compared with 0.75% for ARKG.
XPH has the higher dividend yield at 0.66%, compared with 0.00% for ARKG.
They also come from different issuers: State Street and ARK. Their fees differ too: 0.35% for XPH and 0.75% for ARKG.
XPH currently has the higher Sharpe Ratio (1.77 vs 1.31), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XPH and ARKG
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer